Michael Hoek - Shuttle Pharmaceuticals Vice Regulatory
| SHPH Stock | USD 4.01 0.13 3.14% |
Executive
Michael Hoek is Vice Regulatory of Shuttle Pharmaceuticals
| Age | 65 |
| Address | 401 Professional Drive, Gaithersburg, MD, United States, 20879 |
| Phone | 240 403 4212 |
| Web | https://www.shuttlepharma.com |
Shuttle Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.7569) % which means that it has lost $1.7569 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.5104) %, meaning that it created substantial loss on money invested by shareholders. Shuttle Pharmaceuticals' management efficiency ratios could be used to measure how well Shuttle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The Shuttle Pharmaceuticals' current Return On Tangible Assets is estimated to increase to -3,466. The Shuttle Pharmaceuticals' current Return On Capital Employed is estimated to increase to -7,518. As of now, Shuttle Pharmaceuticals' Other Current Assets are increasing as compared to previous years. The Shuttle Pharmaceuticals' current Non Currrent Assets Other is estimated to increase to about 356.3 M, while Non Current Assets Total are projected to decrease to under 172.9 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brikkelle Thompson | Lifecore Biomedical | N/A | |
| Thomas Salus | Lifecore Biomedical | 56 | |
| Steve Laninga | Lifecore Biomedical | N/A | |
| Matt Augustson | Lifecore Biomedical | N/A | |
| Joel Yeung | Virax Biolabs Group | N/A | |
| Dallas Coleman | bioAffinity Technologies, | N/A | |
| James Wang | Virax Biolabs Group | N/A | |
| Gordon MD | bioAffinity Technologies, | N/A | |
| Thomas Guldager | Lifecore Biomedical | N/A | |
| Nigel MSc | Virax Biolabs Group | 60 | |
| Jackie Klecker | Lifecore Biomedical | N/A | |
| Lily Fu | Virax Biolabs Group | N/A | |
| William Bauta | bioAffinity Technologies, | N/A | |
| Kara Morley | Lifecore Biomedical | N/A | |
| Darren Hieber | Lifecore Biomedical | N/A | |
| Mark DaFonseca | Lifecore Biomedical | N/A | |
| Clement Monteil | Virax Biolabs Group | N/A | |
Management Performance
| Return On Equity | -5.51 | ||||
| Return On Asset | -1.76 |
Shuttle Pharmaceuticals Leadership Team
Elected by the shareholders, the Shuttle Pharmaceuticals' board of directors comprises two types of representatives: Shuttle Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shuttle. The board's role is to monitor Shuttle Pharmaceuticals' management team and ensure that shareholders' interests are well served. Shuttle Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shuttle Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, President COO | ||
| Michael Starkweather, VP Devel | ||
| CSC MD, Chief CoFounder | ||
| Timothy CPA, Chief Officer | ||
| BBA MBA, Interim Officer | ||
| Gene Esq, General Counsel | ||
| Mira Jung, CoFounder Biology | ||
| Tyvin MD, Chief Officer | ||
| Anatoly MD, CoCEO, CoFounder | ||
| Michael Hoek, Vice Regulatory |
Shuttle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Shuttle Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.51 | ||||
| Return On Asset | -1.76 | ||||
| Current Valuation | 333.66 K | ||||
| Shares Outstanding | 1.07 M | ||||
| Shares Owned By Insiders | 5.82 % | ||||
| Shares Owned By Institutions | 5.67 % | ||||
| Number Of Shares Shorted | 16.05 K | ||||
| Price To Book | 1.23 X | ||||
| EBITDA | (7.78 M) | ||||
| Net Income | (9.14 M) |
Currently Active Assets on Macroaxis
| NOAH | Noah Holdings | |
| CIG | Companhia Energetica de | |
| BBVA | Banco Bilbao Viscaya | |
| ENIC | Enel Chile SA | |
| SBSW | Sibanye Gold Ltd |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Shuttle Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shuttle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.